Evidence accumulated over the years suggests that human erythrocyte membrane protein 4.2 is one of the proteins involved in strengthening the cytoskeleton-membrane interactions in the red blood cell. Deficiency of protein 4.2 is linked with a variety of hereditary haemolytic anaemia. However, the interactions of protein 4.2 with other proteins of the erythrocyte membrane remain poorly understood. The major membrane-binding site for protein 4.2 resides on the cytoplasmic domain of band 3 (CDB3). In order to carry out an initial characterization of its interaction with the CDB3, protein 4.2 was subjected to proteolytic cleavage and gel renaturation assay, and the 23-kDa N-terminal domain was found to interact with band 3. This domain contained two putative palmitoylatable cysteine residues, of which cysteine 203
INTRODUCTION
In the red blood cell, the flexible and elastic meshwork of proteins underlying the lipid bilayer comprises the cytoskeleton and is responsible for maintaining the bi-concave shape of the erythrocyte, for its reversible deformability and for membrane structural integrity [1] [2] [3] . Spectrin tetramers interact with actin, protein 4.1 and adducin to form the cytoskeleton network [4] [5] [6] [7] [8] . This network is linked to the membrane through interactions between protein 4.1, p55 and glycophorin [9] [10] [11] [12] ; through ankyrin, which binds to the β-subunit of spectrin and attaches it to the membrane via band 3 [13, 14] ; through interactions between protein 4.2 and band 3 ; and through weak interactions of spectrin and protein 4.1 with the negatively charged lipids of the inner half of the bilayer [15, 16] . A structural model has emerged that predicts two types of interaction : the vertical protein interactions ensure the anchoring of the skeleton to the lipid bilayer and comprise mainly the binding of band 3 to ankyrin, ankyrin to spectrin, glycophorin C to protein 4.1 and protein 4.2 to band 3. The horizontal protein interactions account for the lateral deformability and extensibility of the skeleton and consist mainly of spectrin dimer-dimer interactions and the spectrinprotein 4.1-actin-binding complex.
Protein 4.2 is a 72-kDa peripheral membrane protein that comprises approx. 5 % of the total membrane protein [17] [18] [19] [20] . It is present in 2i10& copies per red cell [21] . The importance of this protein has recently been recognized through studies that have shown that protein 4.2 deficiency results in overt haemolysis, anaemia and a borderline variety of hereditary spherocytosis [22] [23] [24] [25] [26] . The gene for protein 4 
.2 has been cloned and sequenced
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was identified as the palmitoylatable cysteine. Recombinant glutathione S-transferase-fusion peptides derived from this domain were characterized with respect to their ability to interact with the CDB3. Whereas these studies do not rule out the involvement of other subsites on protein 4.2 in interaction with the CDB3, the evidence suggests that the region encompassing amino acid residues 187-211 is one of the domains critical for the protein 4.2-CDB3 interaction. This is also the first demonstration that palmitoylation serves as a positive modulator of this interaction.
Key words : anion exchanger, cytoskeleton, palmitoylation.
[ 27, 28] . The protein shares significant sequence similarity with the transglutaminase family of enzymes and the gene for protein 4.2 is remarkably similar to the genes for human coagulation factor XIII and keratinocyte transglutaminase [29, 30] [35] and palmitoylated [36] . It can be phosphorylated by a red-cell-membrane kinase that partially co-purifies with it, and has properties similar to the catalytic subunit of cAMP-dependent kinase [37] . In addition, protein 4.2 shares a conserved 11-amino acid motif with dematin, which contains an ATP-binding P-loop [38] . Whereas it has been observed that the band 3-cytoskeleton linkage is weakened in protein 4.2-deficient membranes [39] , there is an obvious gap in our knowledge at the molecular level of the interactions of protein 4.2 with band 3. In view of this, our objectives were to characterize the domains of protein 4.2 involved in the interaction with the cytoplasmic domain of band 3 (CDB3) of the human erythrocyte, to identify the site(s) of palmitoylation of protein 4.2 and to find out the role, if any, of palmitoylation in regulating the protein 4.2-CDB3 interaction.
EXPERIMENTAL PROCEDURES SDS/PAGE
Protein samples were separated on the basis of their molecular mass by SDS\PAGE according to the method of Laemmli [40] . SDS\PAGE using the discontinuous procedure of Schagger and von Jagow [41] was used for visualizing polypeptides of 2.5-17 kDa. Radiolabelled protein samples contained in SDS gels were visualized by fluorography according to the method of Bonner and Laskey [42] .
Electroblotting on to PVDF and N-terminal sequencing
Electroblotting on to PVDF membranes was carried out as described by Matsudaira [43] . N-terminal sequencing was performed on an Applied Biosystems model 477A Pulsed Liquid Sequenator with online analysis of the phenylthiohydantoin amino acids by HPLC at the protein-sequencing facility of Eurosequence, Groningen, The Netherlands.
Preparation and radiolabelling of cells
Blood was collected from normal, healthy human volunteers in Dulbecco's modified Eagle's medium (DMEM). Cells were collected by centrifugation and washed with DMEM to remove the buffy coat. Packed erythrocytes (120 µl) were incubated at 37 mC with DMEM (8 ml) containing 20 µCi [9,10-$H]palmitic acid (Amersham International) and 161 µg of fatty acid-free BSA. After 3 h, cells were pelleted, washed five times with DMEM containing 5 mg\ml BSA, twice with 155 mM NaCl\ 7.5 mM sodium phosphate\0.1 mM Na # EDTA (pH 7.5) and lysed with lysis buffer (7.5 mM sodium phosphate, pH 7.5) containing 1 mM PMSF, 0.1 mM leupeptin and 30 µg\ml aprotinin. Ghosts were precipitated by centrifugation at 38 000 g (Sorvall SS-34 rotor) for 20 min, followed by two washes in lysis buffer.
Purification and radio-iodination of protein 4.2
Human erythrocyte protein 4.2 was purified as described by Das et al. [36] . Protein 4.2 was radiolabelled with N-succinimidyl-3-(4-hydroxy-5-["#&I]iodophenyl)propionate (Bolton-Hunter reagent) [44] and dialysed against 5 mM sodium phosphate\ 0.5 mM EGTA\0.5 mM dithiothreitol\120 mM KCl (pH 8). 
Purification of the CDB3 and biotinylation
Purification of CDB3 was performed according to Bennett [47] . Biotinylation was performed as described in the Pierce NHSiminobiotin (N-hydroxysuccinimidoiminobiotin hydrobromide) instruction manual. Purified CDB3 (5 mg\ml) was taken in 500 µl of 0.1 M Hepes (pH 8.0) and treated with 50-100 fold molar excess of NHS-iminobiotin dissolved to 1 mg\ml in DMSO. After incubation on ice for 2 h the biotinylated CDB3 was dialysed against the appropriate buffer.
Blot-overlay assay
This assay was performed as described by Platt et al. [48] . Tween 20] , the blot was incubated with 1 µM biotinylated CDB3 for 1 h at room temperature. After the blot was washed with ligand buffer, it was incubated with 2 µg\ml streptavidin-alkaline phosphatase for 30 min at room temperature. After three washes, the colour was developed with 5-bromo-4-chloro-3-indolyl phosphate and Nitro Blue Tetrazolium (BCIP\NBT).
Construction of recombinant proteins
To produce recombinant proteins, defined domains of protein 4.2 were amplified from protein 4.2 cDNA in the vector pGEM3z (a gift of Professor Carl Cohen, St. Elizabeth's Hospital, Boston, MA, U.S.A.) by PCR. The primers for the constructs are given in Table 1 . The PCR-amplified products were purified, cloned in the vector pK19 [49] , sequenced using the Sequenase Version 2.0 T7 DNA Sequencing Kit from United States Biochemicals, and finally transferred to the vector pGEX-3X (Pharmacia) using asymmetric BamHI and EcoRI sites present in the PCR products.
Expression and purification of fusion proteins
Recombinant fusion proteins were expressed in Escherichia coli BL21 or E. coli DH5α. Expression of protein was carried out in the presence of 0.1 mM isopropyl thiogalactopyranoside (IPTG) at 30 mC. After harvesting of the cells, the cell pellet was suspended in 50 mM Tris\HCl (pH 8)\5 mM EDTA\50 mM NaCl containing 0.15 mM PMSF, 1 mM pefabloc, 1 µg\ml leupeptin, 1 µg\ml pepstatin, 5 mM β-mercaptoethanol and 1 % (w\v) Triton X-100, and disrupted by sonication on a Labsonic 2000 sonicator (B. Braun) for a maximum of 10 s, avoiding frothing. The post-sonicate pellet was extracted with 50 mM Tris\HCl (pH 8) containing 5 M urea, 0.15 mM PMSF, 1 mM pefabloc, 1 µg\ml leupeptin, 1 µg\ml pepstatin and 5 mM β-mercaptoethanol using a Dounce homogenizer and incubated for 2 h on ice. The mixture was centrifuged at 100 000 g for 1 h and the supernatant was dialysed for 3 h at 4 mC against renaturation buffer containing 126.6 mM NaCl, 10 mM sodium phosphate (pH 7.3), 5 mM β-mercaptoethanol, 5 mM EDTA, 20 % glycerol, 1 % Triton X-100, 0.15 mM PMSF, 1 mM pefabloc, 0.1 µg\ml leupeptin and 0.1 µg\ml pepstatin. This was followed by dialysis overnight against 126.6 mM NaCl\10 mM sodium phosphate\ 5 mM EDTA\0.15 mM PMSF\1 % Triton X-100 (pH 7.3). Renatured fusion proteins were purified from the urea extract by affinity chromatography on glutathione-Sepharose.
Purification of the erythrocyte protein palmitoyl acyltransferase (PAT) and determination of the stoichiometry of palmitoylation by immunoprecipitation
Purification of the erythrocyte protein PAT was carried out as described by Das et al. [50] . The stoichiometry of palmitoylation of each of the recombinant proteins was also determined as described by Das et al. [50] . Briefly, varying amounts of the recombinant proteins (2-6 µg) were incubated with 40 µM ["%C]palmitoyl-CoA (50 mCi\mmol ; Amersham International) and erythrocyte PAT (10 µg\ml) in 100 mM imidazole buffer (pH 7.5) for 60 min. Recombinant proteins were immunoprecipitated using anti-GST antibody and Staph. aureus Protein A, and the radioactivity associated with the bound antigenantibody complex was counted in a liquid scintillation counter.
Binding assay for studying the interaction between protein 4.2-derived recombinant polypeptides and the CDB3
Where applicable, recombinant proteins were palmitoylated. Palmitoylation was checked by SDS\PAGE and fluorography. Proteins (40-80 µg in 100 µl) were adsorbed to the wells of a microtitre ELISA plate. Adsorption was allowed to proceed for 12 h at 4 mC. The wells were washed with PBS containing 0.5 % Tween (PBS-T). Non-specific binding sites were blocked with blocking buffer [1 % (w\v) BSA in PBS-T] for 1 h at 37 mC. The wells were washed extensively with PBS-T. Biotinylated CDB3 [100 µl ; 0.2-10 µM] was added to each well and the binding was allowed to proceed for 6 h at room temperature. The wells were then washed extensively with PBS-T. Binding of biotinylated CDB3 was measured by adding 0.1 µg\ml (in 100 µl) streptavidin-alkaline phosphatase to each well and incubating for 60 min at room temperature. This was followed by colour development by the addition of 1 mg\ml p-nitrophenyl phosphate prepared in 0.1 M glycine containing 0.01 M MgCl # (pH 10.4). Absorbance was measured at 405 nm. In each case, control experiments were performed in which equivalent amounts of BSA were first adsorbed to the wells. Controls were also run using recombinant GST alone.
The inhibition of the association of protein 4.2 with biotinylated CDB3 by recombinant fusion protein was studied by allowing ["#&I]protein 4.2 (18-72 µg\ml) to interact with biotinylated CDB3 (40 µg) in a 100-µl vol. of 120 mM KCl\5 mM sodium phosphate\0.1 mM EGTA\20 µg\ml PMSF\0.5 mM dithiothreitol\1 mg\ml gelatin (pH 8). This was at room temperature in the absence or presence of different concentrations of palmitoylated or non-palmitoylated recombinant fusion protein. Streptavidin-agarose (10 µl of a 50% slurry) was then added to each tube, followed by incubation for 30 min at room temperature. The suspension was centrifuged at 2000 g in a clinical centrifuge, the streptavidin-agarose beads were washed twice with 100 µl of binding buffer, and the pellet was counted in a γ-counter. Control experiments lacking biotinylated CDB3 were run in parallel to account for non-specific binding.
RESULTS

Partial proteolysis of labelled protein 4.2 and blot-overlay assay
Electroeluted protein 4.2 was proteolysed partially with staphylococcal V8 protease and loaded in three separate lanes of a denaturing SDS\polyacrylamide gel. After running the gel, one lane was stained with Coomassie Brilliant Blue and subjected to fluorography (in order to identify the site of palmitoylation), the proteins of a second lane were transferred on to a nitrocellulose membrane (for blot-overlay assay) and the proteins of a third lane were transferred on to a PVDF membrane (for N-terminal sequencing).
The proteins transferred on to nitrocellulose were renatured as described. After incubation with blocking buffer in order to block non-specific binding, the renatured proteins were incubated with biotinylated CDB3 followed by successive incubations with streptavidin-alkaline phosphatase and a mixture of BCIP\NBT. It was observed that a 23-kDa band developed colour ( Figure  1A, lane b) . This 23-kDa polypeptide was therefore likely to 203 C* represents the putative palmitoylatable cysteine residue. The positions of molecular-mass markers have been indicated. Amino acid numbering is according to that of Sung et al. [28] .
represent the band-3-interacting domain. A 23-kDa polypeptide also gave a band after fluorography ( Figure 1A , lane a), indicating that it was palmitoylated. No other band appeared after fluorography.
N-terminal sequencing
The 23-kDa polypeptide blotted on to a PVDF membrane was subjected to N-terminal sequencing and found to be N-terminally blocked. This suggested that the 23-kDa polypeptide represented the N-terminal domain of protein 4.2, since the N-terminus of protein 4.2 is blocked by N-myristoylation. The different Nterminal domains of protein 4.2 referred to subsequently are represented in Figure 1(C) . The 23-kDa polypeptide was subjected to cleavage by CNBr, taking note of the fact that the predicted domain contained only one methionine residue at position 186. CNBr treatment would cleave this domain into polypeptides of approx. 16 000 (containing one putative cysteine residue at position 40) and 6500 Da (containing one putative cysteine residue at position 203). Treatment of the [$H]palmitatelabelled 23-kDa fragment with CNBr, followed by SDS\PAGE and fluorography, showed that only one 6.5-kDa peptide was labelled ( Figure 1B ). Protein 4.2 therefore appeared to contain only one palmitoylatable cysteine at position 203. N-terminal sequencing showed that, as predicted, the 16-kDa peptide was N-terminally blocked and the N-terminal sequence of the 6.5-kDa peptide was ")(Glu-Tyr-Leu-Leu-Asn-Gln-Asn-GlyLeu-Ile-Tyr"*(.
In connection with the above experiments, in particular partial proteolysis with V8 protease, it is pertinent to mention that molecular-mass determination by SDS\PAGE is approximate. The more accurate methods of mass spectrometry could not be used here, since these would have been hampered by the presence of SDS (V8 protease digestion having been performed in the presence of SDS). However, the span of the 23-kDa domain was determined after taking several points into careful consideration. Cleavage at Glu-254 would generate a fragment of 22.6 kDa, whereas cleavage at Glu-268 would yield a fragment of 24.2 kDa. In the first instance, subsequent CNBr cleavage would yield fragments of 16 and 6.6 kDa respectively. In the second instance, fragments of 16 and 8.2 kDa respectively would be obtained. For practical purposes it was considered sufficient to consider the molecular masses of the amino acids only and exclude the post-translational modifications such as myrist-Band-3-binding domain of protein 4.2
Figure 2 Purification of the recombinant fusion proteins
Coomassie Brilliant Blue-stained SDS/polyacrylamide gels of the fusion proteins purified on glutathione-Sepharose 4B. Lanes a-f represent the proteins C2, C3, R2, B1, R3 and R1 respectively. The positions of molecular-mass markers have been indicated. oylation and palmitoylation. Since Shagger and von Jagow [41] gels that had been run with appropriate molecular-mass markers showed the presence of polypeptides of 16 and 6.5 kDa, it was assumed that the N-terminal V8 protease-generated polypeptide terminated at Lys-253.
Expression of recombinant GST-fusion proteins
Expression of fusion proteins in E. coli was chosen as a strategy for studying the binding of these domains with the CDB3. The rationale was that the fusion proteins expressed in E. coli would represent the non-palmitoylated state, since palmitoylation does not occur in the prokaryote, and that these fusion proteins could be palmitoylated subsequently by the erythrocyte PAT and the binding with CDB3 assessed.
Expression of fusion proteins spanning amino acid residues 31-185 (C2) and 187-260 (C3) was carried out by induction with 0.1 mM IPTG at 30 mC and fusion proteins of the desired size (i.e. approx. 33 and 42 kDa for C3 and C2 respectively) were expressed. The expression of C2 was not to the level of that observed for C3, and some amount of a band corresponding to GST was always observed. The harvested cells were sonicated with a brief pulse. After centrifugation, the supernatant and the pellet were analysed by SDS\PAGE. The majority of the fusion proteins were found in the post-sonicate pellet. Decreasing the temperature used for induction with IPTG, or the concentration of IPTG, failed to produce better results. Solubilization was achieved with urea, the urea extract was allowed to adsorb to glutathione-Sepharose 4B and elution was carried out with glutathione. The presence of 0.1 % Triton X-100 in the elution buffer was found to be essential for efficient elution of the fusion protein. C3 was purified to 90 % purity (Figure 2 ). Efforts to purify C2 yielded, at best, low amounts of this fusion protein from the glutathione-Sepharose 4B resin. Attempts to express and purify fusion proteins encompassing amino acid residues 31-260 (i.e. the N-terminal 23-kDa domain) as well as full-length protein 4.2 were not successful.
Palmitoylation of fusion proteins with the erythrocyte PAT
The purified fusion protein (3 µg) was palmitoylated with 40 µM ["%C]palmitoyl CoA in the absence or in the presence of erythrocyte PAT, and run on an SDS\polyacrylamide gel, followed by fluorography. From Figure 3 (A) it is evident that the palmitoylation of C3 was mediated by the erythrocyte PAT. No palmitoylation was observed in the absence of the enzyme. C2 could not be palmitoylated. Recombinant GST was run as a 
Blot-overlay assay
The palmitoylated C3 was obtained by acylation of the purified protein in the presence of erythrocyte PAT, followed by purification on glutathione-Sepharose 4B. A blot-overlay assay with recombinant fusion proteins (3 µg) and biotinylated CDB3 was performed. No band was obtained corresponding to C2 ( Figure  3B ). This experiment therefore could not demonstrate interaction between the 16-kDa N-terminal domain of protein 4.2 and CDB3. Positive bands were obtained with C3 in its palmitoylated and non-palmitoylated form ( Figure 3B) . However, the intensity of the band was more in the case of the palmitoylated fusion protein. This suggested that palmitoylation could modulate positively the interaction of the fusion protein with the CDB3. No colour development was observed in the control run with the recombinant GST alone, suggesting that non-specific interactions between GST and the CDB3 were not responsible for the colour development observed with the recombinant fusion protein.
Since, from the blot-overlay assay, C3 and not C2 appeared to interact with the CDB3, only the interaction of C3 with the CDB3 was studied further.
Interaction of C3 with CDB3
The interaction of C3 with CDB3 was studied by first allowing the recombinant fusion proteins to bind to microtitre plates, followed by successive incubations with biotinylated CDB3, streptavidin-alkaline phosphatase and p-nitrophenyl phosphate. The A %!& values obtained were converted to micrograms of CDB3 bound by preparing a standard curve of A %!& versus [biotinylated CDB3]. In each experiment, recombinant GST alone was run as a control. It did not interact with the CDB3. Non-specific binding (i.e. readings obtained for BSA or GST) was less than 15 %. It was observed that C3 interacted with the CDB3. Five experiments were performed using different preparations of the CDB3 and recombinant fusion proteins. The
Figure 4 Scatchard analysis of the interaction of C3 with the CDB3
The binding of palmitoylated (A) and non-palmitoylated (B) fusion proteins with biotinylated CDB3 were assayed in microtitre plates. Data were analysed using the non-linear-regression curve-fitting software ENZFITTER (Elsevier Biosoft).
Scatchard plot appeared linear (Figure 4) , suggesting a single class of sites interacting with the CDB3. The K d values of the non-palmitoylated form ranged from 1.7 to 3.6 µM, wheareas the K d values of the palmitoylated form ranged from 0.6 to 1.8 µM. Variations in K d values similar to those obtained during this study have been reported by Korsgren and Cohen [31] . Figure 4 shows a representative set of data of the interaction of the CDB3 with the palmitoylated and the non-palmitoylated forms of the fusion protein. A pairwise comparison of data for the palmitoylated and the non-palmitoylated fusion proteins from each of the five sets of experiments showed at least a 3-fold decreased K d value for the palmitoylated form, suggesting that palmitoylation enhances the affinity of the fusion protein for the CDB3. The K d values suggest that it is likely to represent an important domain of protein 4.2 involved in interaction with the CDB3.
Inhibition of the interaction of [
I]protein 4.2 with the CDB3 by C3
In conformity with the previous observations, it was found that the interaction of ["#&I]protein 4.2 with the CDB3 could be inhibited by C3 ( Figure 5 ). Recombinant GST alone could not inhibit the interaction (data not shown). Non-specific binding was less than 15 %. Palmitoylation increased the inhibitory ability of the fusion protein. No further inhibition was observed with increasing concentrations of recombinant fusion protein. [51, 52] . In view of this it was thought to be relevant to analyse whether recombinant proteins encompassing these residues were more efficient in binding to the CDB3 than the recombinant C3. In an effort to map the minimal domain of protein 4.2 involved in binding to the CDB3, several more recombinant proteins were expressed (Table 1) , purified as described in the case of C3 (Figure 2) , and their binding to the CDB3 was studied using the assay described. Recombinants carrying the palmitoylatable cysteine were palmitoylated (in a molar ratio of 1 : 1 of fatty acid to protein). Figure 5 ). Recent studies have demonstrated elegantly, in several instances, the ability of palmitoylation to modulate proteinprotein interactions. Such effects are likely to be mediated by subtle local changes in protein conformation induced by protein palmitoylation. Recently, palmitoylation of the α subunit of the guanine nucleotide-binding protein G z has been shown to inhibit its response to the GTPase-accelerating activity of G z GTPaseactivating protein, a member of the regulators of G-protein signalling protein family of GTPase-activating proteins [55] . In our studies, palmitoylation was found to enhance the affinity of the proteins C3, B1 and R1 for the CDB3. The effect was observed consistently, suggesting that it was likely to bear a significance in modulating the vertical interactions between the erythrocyte membrane and the cytoskeleton in a manner which remains to be understood fully. The fact that depalmitoylation by hydroxylamine treatment of native protein 4.2 resulted in a more pronounced effect in terms of the binding of protein 4.2 to the membrane [36] than evidenced in our experiments with the recombinant proteins could be due to either of two reasons. Hydroxylamine could possibly alter the native conformation of the protein. Alternatively, palmitoylation of protein 4.2 could, in addition to bringing about local changes in protein 4.2 conformation, also result in additional associations of the palmitate moiety with the hydrophobic components of the membrane, resulting in increased affinity of protein 4.2 for the membrane, a factor which does not arise when studying protein 4.2-CDB3 interactions. The effects of protein 4.2 palmitoylation are likely to be complex and multifaceted. The importance of the present study rests in the fact that not only is it one of the first documented reports on mapping the domain of protein 4.2 participating in interaction with the CDB3, but that it also provides, for the first time, insights into the potential role of palmitoylation in modulating protein 4.2-membrane interactions.
